Evidence map›Paper›PMID 42213823›Full record

ArticleScience advances2026

EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach.

Misbah Aziz, Karly C Sourris, Jairo A Pinzon-Cortes, Tomasz J Block, Aozhi Dai, Scott Maxwell, Jun Okabe, Anna C Calkin, Mark E Cooper, Karin A M Jandeleit-Dahm and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Misbah AzizDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0002-8593-1028
Karly C SourrisDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Jairo A Pinzon-CortesDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0002-9299-2048
Tomasz J BlockDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Aozhi DaiDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0003-3341-6646
Scott MaxwellDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0002-7801-0714
Jun OkabeDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0002-7196-0522
Anna C CalkinBaker Heart and Diabetes Institute, Melbourne, Australia.
Mark E CooperDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-7785-2488
Karin A M Jandeleit-DahmDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Abdul Waheed KhanDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-6626-6897

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis drives cardiovascular morbidity in diabetes, with endothelial-to-mesenchymal transition (EndMT) as a key contributor. Whereas epigenetic regulators are increasingly implicated in atherosclerotic progression, the specific role of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, in EndMT in diabetes-associated atherosclerosis remains unclear. We show that EZH2-mediated H3K27 (histone H3 at lysine-27) trimethylation is elevated in carotid plaques from patients with diabetes and in the aortic endothelium of diabetic

Indexed as

AtherosclerosisEndothelial-Mesenchymal TransitionEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticIndazolesPyridonesAnimalsDiabetes Mellitus, ExperimentalEndothelial CellsHistonesHumansIndolesMaleMiceEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanGSK-2816126HistonesIndazolesIndolesPyridones

Identifiers

PMID42213823
PMCPMC13220873

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.